'Cancer' labeling: article largely about DCIS, but endless analogies to Gleason 6/Grade Group 1 prostate cancer Hopefully, tides are a turning.....

Experts Are Debating Whether Some Cancers Shouldn’t Be Called That

We asked three big-brained superstars to share thoughts on a very important topic...... My $0.02: "potentially clinically significant" far more accurate than "clinically significant"

Powerful data, we can/should do better Similar/better benefit than many extraordinarily expensive drugs Right up alley of @RichMatulewicz, Andrea King UofC

World champ?? Ronald Weiss was known to perform 14 vasectomies in a day and was done by lunch via @WSJ

@BenMazer

G-Minor-ambitious, exciting, and a clinically relevant question: Kudos to MUSIC patients/investigators: Editorial by @oncostan and me: Plz discuss @wandering_gu @DrSpratticus @peepeeDoctor @KBGinsburg @redunndant @hollenbeck1971

More data/modeling to inform the GG1/Gleason 6 relabeling debate. Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling

Powerful essay by co fellow and close friend Joe Pettus. Some new twist and insights into the age-old “when the doctor becomes patient” When One Day Becomes Today

@UroOncologist As a Bears fan, guess I’m the surgeon who got bumped for your case

Data suggesting more people with PrCa (current or treated) should be getting timely organ transplants. Zero evidence (to my knowledge) immunosuppression alters natural history of PrCa. @twattskristof @AaronDahmen @wandering_gu

@joniau @ChapinMD @CanesDavid @uretericbud @KeithKow @daviesbj @TheGiesen @heinvanpoppel Steve, agree re PSA>20 (very rare and often undiagnosed higher ISUP) In 2500 men with post-RP G6, ECE 0.28% and SVI 0%. Not aware of a single case of modern G6 with SVI Some series have higher ECE rate but doesn't impact BCR so shouldn't matter right?

@joniau @ChapinMD @CanesDavid @uretericbud @KeithKow @daviesbj @TheGiesen @heinvanpoppel C'mon Steve. Cohort starts in 1989, era of sextant biopsy, no MRI, two separate Gleason scoring changes since (2005/2014), nearly half GG1 were T3/T4 (?!?!) which in a modern series is 0.28% of the time (. This is a straw-man argument and not relevant.

Whether you are an advocate of thoughtful PSA screening and treatment of localized disease OR argue vociferously against it, please digest this 30 year data (and remember it was largely palpable disease)

@ZSchwen @CleClinicUro Jim/Zayed, the RCT data doesn’t exactly equate to “blown away” and not aware of any proven benefit for erections (but could be wrong). I’m not opposed to the technique, have done it, but def less enthusiastic than y’all.

@VickersBiostats Big props to patients and investigators for doing the trial. No benefit but major limitation was median node count between two arms was 12 vs 14. Will be interesting to see what other ongoing RCTs show regarding node dissections in prostate cancer.

@RenoHemonc Fraught with limitations. Innumerable cancers w retrospective data suggesting more nodes a/w better outcome. Very different than RCT.

@fazekasMD So do I. Studies/trials in process to find out.